Rodrîguez-Panadero F, Borderas Naranjo F, López Mejîas J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J. 1989 Apr;2(4):366–9.

Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res. 2017;23(9):229–41.

Article  Google Scholar 

Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–104.

Article  Google Scholar 

Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010 Aug 1;65(Suppl 2):ii32–40.

Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127(3):909–15.

Article  Google Scholar 

Yamada S, Mitarbeitern. Über die seröse Flüssigkeit in der Pleurahöhle der gesunden Menschen. 1933.

Broaddus VC. Physiology: fluid and solute exchange in normal physiological states. In: Textbook of Pleural Diseases. 2nd ed. CRC Press; 2008.

Lee YCG, Clelland CA, Rahman NM. PLEURAL SPACE. In: Laurent GJ, Shapiro SD, editors. Encyclopedia of respiratory medicine. Oxford: Academic Press. 2006;[cited 2022 Aug 18]:397–402. Available from: https://www.sciencedirect.com/science/article/pii/B0123708796005081

Miserocchi G. Mechanisms controlling the volume of pleural fluid and extravascular lung water. Eur Respir Rev. 2009;18(114):244–52.

Article  CAS  Google Scholar 

Pistolesi M, Miniati M, Giuntini C. Pleural liquid and solute exchange. Am Rev Respir Dis. 1989;140(3):825–47.

Article  CAS  Google Scholar 

Hatzoglou CH, Gourgoulianis KI, Molyvdas PA. Effects of SNP, ouabain, and amiloride on electrical potential profile of isolated sheep pleura. J Appl Physiol (1985). 2001 Apr;90(4):1565–9.

Jany B, Welte T. Pleural effusion in adults—etiology, diagnosis, and treatment. Dtsch Arztebl Int. 2019;116(21):377–86.

Google Scholar 

Ryu JS, Ryu ST, Kim YS, Cho JH, Lee HL. What is the clinical significance of transudative malignant pleural effusion? Korean J Intern Med. 2003;18(4):230–3.

Article  Google Scholar 

Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189–98.

Article  Google Scholar 

Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med. 1977;63(5):695–702.

Article  CAS  Google Scholar 

Andrews BS, Arora NS, Shadforth MF, Goldberg SK, Davis JS. The role of immune complexes in the pathogenesis of pleural effusions. Am Rev Respir Dis. 1981;124(2):115–20.

CAS  Google Scholar 

Spella M, Giannou AD, Stathopoulos GT. Switching off malignant pleural effusion formation—fantasy or future? J Thorac Dis. 2015;7(6):1009–20.

Google Scholar 

Fafliora E, Hatzoglou C, Gourgoulianis KI, Zarogiannis SG. Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. Physiol Rep. 2016;4(24): e12978.

Article  Google Scholar 

Acencio MMP, Puka J, Alvarenga VA, Martins V, de Carvalho MLP, Marchi E, et al. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion. Oncotarget. 2017;8(62):105093–102.

Article  Google Scholar 

Meyer PC. Metastatic carcinoma of the pleura. Thorax. 1966;21(5):437–43.

Article  CAS  Google Scholar 

Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383–9.

Article  CAS  Google Scholar 

• Boshuizen RC, Vincent AD, van den Heuvel MM. Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion. Support Care Cancer. 2013 Nov;21(11):3109–16. Boshuizen et al. undertook a prospective study of 64 MPE patients to investigate features associated with the need for pleural re-intervention.

• Grosu HB, Molina S, Casal R, Song J, Li L, Diaz‐Mendoza J, et al. Risk factors for pleural effusion recurrence in patients with malignancy. Respirology. 2019 Jan;24(1):76–82. Grosu et al. conducted a retrospective cohort study of 988 participants with MPEs. They aimed to identify risk factors for pleural fluid recurrence following initial thoracocentesis.

Negrini D, Mukenge S, Del Fabbro M, Gonano C, Miserocchi G. Distribution of diaphragmatic lymphatic stomata. J Appl Physiol. 1991;70(4):1544–9.

Article  CAS  Google Scholar 

Zocchi L, Agostoni E, Raffaini A. Effect on phloridzin on net rate of liquid absorption from the pleural space of rabbits. Exp Physiol. 1996;81(6):957–67.

Article  CAS  Google Scholar 

Lai-Fook SJ. Pleural mechanics and fluid exchange. Physiol Rev. 2004;84(2):385–410.

Article  CAS  Google Scholar 

Kouritas VK, Tsantsaridou A, Tepetes K, Tsilimingas N, Gourgoulianis KI, Molyvdas PA, et al. Effect of histamine on the electrophysiology of the human parietal pleura. Mol Cell Endocrinol. 2011;332(1–2):271–6.

Article  CAS  Google Scholar 

Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518–26.

Article  CAS  Google Scholar 

Bradshaw M, Mansfield A, Peikert T. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013;15(3):207–16.

Article  CAS  Google Scholar 

Nie K, Zhang Z, You Y, Zhuang X, Zhang C, Ji Y. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer. Thorac Cancer. 2020;11(1):8–14.

Article  CAS  Google Scholar 

Zongwen S, Song K, Cong Z, Tian F, Yan Z. Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection. Oncotarget. 2017;8(69):113318–30.

Article  Google Scholar 

Biaoxue R, Xiguang C, Hua L, Wenlong G, Shuanying Y. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer. 2016;16(1):888.

Article  Google Scholar 

•• Reaccumulation rate of Malignant Pleural Effusions After Therapeutic Aspiration (REPEAT): an observational cohort study to create a multivariable prediction model of rate of pleural fluid reaccumulation following therapeutic aspiration in patients with malignant pleural effusion attending a pleural clinic - NIHR Funding and Awards. [cited 2022 Aug 7]. Available from: https://fundingawards.nihr.ac.uk/award/NIHR201466. The REPEAT study is currently in enrolment. Mishra et al. aim to identify biomarkers related to MPE recurrence and to develop a clinical score. This will be validated as a predictive tool for MPE recurrence following thoracocentesis.